Inflammation and Autoimmunity
Developing novel treatments for a breadth of inflammatory and autoimmune diseases
Seeking to develop best-in-class and first-in-class treatments for a breadth of inflammatory and autoimmune diseases with unmet medical needs
Leveraging our strength and expertise in immunology science, our research efforts are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease. This approach enables us to identify and select drug targets that have the potential to effectively treat not just one, but multiple inflammatory and autoimmune diseases. Through our advancements in this field, we aim to bring value to the broader scientific community, help redefine standards of care and, ultimately, deliver breakthrough medicines that transform the lives of patients worldwide.
Lupus is a complicated autoimmune disease that can have a profound negative impact on a patient’s quality of life. Innovations in lupus therapies have lagged behind compared to other autoimmune diseases. However, recent developments in understanding the underlying biology of the disease and critical pathways are offering new hope.
Myth vs reality
The role of interferon
Unmet needs in lupus
Understanding the many costs of lupus
Learn more about the burden people with SLE face through indirect costs, including higher levels of unemployment and absenteeism.
The impact of lupus – one patient’s story
Hear more about what it is like to live with this cruel, debilitating disease and how experts in the lupus community believe new, targeted treatments could help.
Type 1 Interferons (IFN) play a critical role in lupus and elevated levels of Type I IFNs are correlated with a more active and severe disease course. The role of the Type I interferon pathway may go beyond lupus; elevated type I IFN gene signature has been found in several other autoimmune diseases. AstraZeneca is investigating how blocking the Type I interferon pathway could lead to new treatment options for interferon-driven disease.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.
Other (as at 27 April 2017)
Brodalumab receives positive CHMP opinion for the treatment of adult patients with moderate-to-severe plaque psoriasis
AstraZeneca presents positive new data on anifrolumab in lupus at American College of Rheumatology Annual Scientific Meeting
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
Date of next review: June 2018